Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Evalve
company
About
Evalve engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $35M
- Industries
- Health Care,Manufacturing,Medical Device
- Founded date
- Jan 1, 1999
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Evalve, Inc. engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves. It provides a non-surgical mitral valve repair system consisting of a steerable guide catheter, a clip delivery system, and an implant device that is used by interventional cardiologists to reduce mitral regurgitation. The company was incorporated in 1999 and is based in Menlo Park, California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$95M
Evalve has raised a total of
$95M
in funding over 2 rounds. Their latest funding was raised on
Nov 27, 2007 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 27, 2007 | Series D | $60M | 1 | — | — | Detail |
| May 25, 2004 | Series C | $35M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Evalve is funded by 1 investors.
Cutlass Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Cutlass Capital
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
